(Q37991405)

26 August 2017

title

Use of the 13-valent pneumococcal conjugate vaccine in infants and young children (English)

1 reference

pneumococcal conjugate vaccine

26 August 2017

main subject

1 reference

2

1 reference

26 August 2017

1

Nicola Principi

1 reference

26 August 2017

language of work or name

English

0 references

publication date

7 March 2012

1 reference

Expert Opinion on Biological Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

641-648

1 reference

Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Pneumococcal necrotizing pneumonia in Utah: does serotype matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Pneumococcal conjugated vaccine: PHiD-CV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Continued impact of pneumococcal conjugate vaccine on carriage in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Community‐acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real‐time polymerase chain reaction using blood samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.670217

10.1517/14712598.2012.670217

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference